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ABSTRACT 
Antipsychotic-induced extrapyramidal symptoms should be recognised and 
adequately treated. We report an unusual complication of not doing so: a 
patient’s self-medicating to control these symptoms, which produced 
diphenhydramine-dependence. 
 
CASE REPORT 
   XY is a fifty-year-old single gentleman living alone; his elderly parents live 
nearby. Paranoid schizophrenia was diagnosed at the age of 19.  He has had 
numerous psychiatric hospital admissions, but has been generally stable over 
recent years, while receiving support from the local assertive outreach team.  
   He is an only child. Slight cyanosis was present at birth, but early 
development was unremarkable. He grew up as an overanxious and sensitive 
child. At school he was bullied extensively, compounding anxiety symptoms to 
a degree warranting assessment by a child psychiatrist at age 13. Enuresis 
persisted until adolescence. Academically he did well, and left school with a 
number of ‘A’ levels. He went to university to read psychology, but left within a 
week, returning with early signs of paranoid schizophrenia: morbid thoughts 
emanating from passers-by suggesting that he hit others; he heard an echo of his 
thoughts shouted back at him; and he believed he was wired up so that people 
knew what he was thinking. Owing to the distress caused by these thoughts, he 
found it difficult to sleep and concentrate, and decided to abandon his university 
studies. Subsequently he had a number of short-term jobs, but since his mid-
twenties has been out of work. He has had brief relationships with women, but 
has no children, and never married. He smokes 40 cigarettes a day and drinks a 
variable amount of alcohol in the form of beer, not exceeding 10-15 units per 
week. Cannabis has been used on occasion. Apart from his mother’s history of 
“emotional difficulties,” there is no family history of psychiatric illness or 
substance abuse. 
   A variety of antipsychotic drugs have been prescribed, mostly as serial 
monotherapy: chlorpromazine, thioridazine, haloperidol, sulpiride, pimozide, 
risperidone, and trifluoperazine in oral form, as well as haloperidol and 
flupentixol depots. From the beginning of antipsychotic therapy, procyclidine 
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was prescribed on a routine basis. But about ten years ago, in the midst of 
transfer between psychiatrists during a hospital admission, procyclidine was 
stopped, owing to suspicion of his misusing it. It was restarted at 10 mg once a 
fortnight intramuscularly, following complaints of worsening akathisia, 
dysphoria, and insomnia. His pleas for reinstating the earlier dose went 
unheeded, as the psychiatrist had ongoing suspicion of potential misuse. The 
patient started to experiment with various over-the-counter medications, and 
found partial relief with diphenhydramine; he began taking increasing 
quantities, and within two years was taking 1600 mg/d.  
   His care was transferred to our team five years ago. Recognizing 
diphenhydramine-dependence, as a consequence of poorly treated akathisia, 
olanzapine was substituted for other antipsychotic medication. The daily dose of 
diphenhydramine halved (800 mg/d), but no further reduction succeeded, 
despite numerous attempts by the multidisciplinary team engaged in his care.  
Two voluntary psychiatric hospitalizations took place, with the goal of 
detoxification from diphenhydramine; there was also a goal of initiating 
clozapine. On each occasion XY became unwilling to continue these 
interventions, and discharged himself. Our team concluded that it is dependence 
on the substance that is maintaining the patient’s habit, rather than genuine need 
to treat residual extrapyramidal symptoms.  
   XY remains symptomatic with distressing auditory hallucinations and 
grandiose delusions; and he believes his thoughts are often broadcast on radio 
and television. Orientation, memory, and concentration are satisfactory; insight 
is poor, though compliance with medication has always been good. He 
functions adequately in his daily routine with support. 
 
DISCUSSION 
   Extrapyramidal side-effects, common with high-potency, conventional 
antipsychotic drugs, include parkinsonism, akathisia, dystonia, and dysphoria 
(1). They result from dopaminergic antagonism in the caudate-putamen on 
postsynaptic cholinergic neurons, thereby increasing the cholinergic tone in the 
basal ganglia (2). Procyclidine, benzhexol (trihexyphenidyl), and benztropine 
are antimuscarinic anticholinergic agents that are especially useful in the 
treatment of antipsychotic-induced extrapyramidal side-effects. For akathisia, 
propranolol is more effective than the anticholinergic agents (3). 
   Abuse-potential is higher for benzhexol, apparently because it causes 
euphoria, than it is for procyclidine (4). Diphenhydramine is an H1-blocker that 
also has anticholinergic effects (1). It is commonly used as an over-the-counter 
hypnotic, but has been proved effective in the treatment of akathisia and 
dysphoria. Abuse-potential for antihistamines has not been established: case-
reports exist describing dependence, although without clarification about the 
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context in which the dependence occurred (5). The case of diphenydramine-
dependence reported here, which we believe came about from a patient’s frantic 
self-medication, underscores the importance of timely assessment, recognition, 
and treatment of antipsychotic-induced extrapyramidal side-effects, especially 
in patients on high-potency, first-generation, neuroleptics. In particular, the 
clinician must take care to recognise extrapyramidal dysphoria as well as 
akathisia. A risk of abuse of anticholinergic agents must be borne in mind, but 
the acknowledgment of risk should not lead to reactive and abrupt withdrawal 
of such necessary treatment.  
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